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Renin and angiotensinogen gene expression in experimental diabetes
mellitus. The renin-angiotensin system may play a role in the initiation
and progression of diabetic kidney disease. In this study, the local
intrarenal renin-angiotensin system was examined in streptozotocin-
treated rats maintained moderately hyperglycemic by daily low-dose
insulin injection. Four weeks after induction of diabetes, plasma renin
activity was significantly lower in the diabetic compared to a non-
diabetic control group (diabetes: 2.30 0.30 vs. control: 6.93 1.36ng
Al/ml/hr; P < 0.01). Renal tissue renin content (diabetes: 1.81 0.46
vs. control: 2.05 0.27 Lg Al/mg protein/hr; P < 0.05) and renal renin
mRNA (diabetes: 2.32 0.16 vs. control: 1.89 0.12 pg/Lg RNA; P =
NS) were not different between diabetic and control rats. Renal and
liver angiotensinogen mRNA were lower in the diabetic group. Glomer-
ular renin mRNA was not different between the diabetic and sham
group. The dissociation between systemic renin activity (a decrease),
and in renal renin content or mRNA in the diabetic rats (no change),
suggests a post-translational alteration in renin processing and/or renin
secretion.
Diabetic nephropathy constitutes a major cause of morbidity
and mortality among diabetic patients [1, 2]. A number of
factors participate in the development of microangiopathic
changes at the renal and systemic level, including alterations in
glucose metabolism and changes in systemic and local levels
and responsiveness to vasoactive hormones [3—81. Renal herno-
dynamic alterations play an important pathogenetic role in the
initiation and progression of diabetic nephropathy [4, 9—12].
The renin-angiotensin system has an important role in the
physiologic regulation of the renal microcirculation. In conjunc-
tion with other vasoactive systems, the renin-angiotensin sys-
tem may contribute to the imbalance of resistances present at
the preglomerular and postglomerular sites which are responsi-
ble for glomerular capillary hypertension, a major injurious
factor in the diabetic kidney [9—14].
The relationship between experimental and clinical diabetes
and the renin-angiotensin system is unclear and the available
reports vary widely [15—24]. In general, plasma renin activity
(PRA) has been reported to be low in diabetic nephropathy
[20—22], although some investigators have found elevations in
PRA in diabetic patients with glomerular hyperflltration [23,
24]. Independent from its systemic counterpart, a locally ex-
pressed and regulated renin-angiotensin system in the kidney
may be involved in the control of renal function [25].
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The purpose of the present study was to examine the intra-
renal renin-angiotensin system in streptozotocin-induced exper-
imental diabetes. We measured PRA, tissue renin content
(TRC) as well as renin and angiotensinogen mRNA levels in
moderately hyperglycemic diabetic rats. As well, we examined
the intrarenal distribution of renin and angiotensinogen mRNAs
in the diabetic rat.
Methods
Experimental design
Experiment 1. Thirteen adult male Sprague-Dawley rats,
weighing 250 to 275 g, were administered either streptozotocin
(STZ) in citrate buffer 65 mg/kg intravenously (i.v.) (Sigma
Chemical Co., St. Louis, Missouri, USA) (diabetic group, N =
8) or citrate buffer i.v. (control group, N = 5). Two days later
blood glucose levels were determined and rats with blood
glucose of greater than 300 mg/dl were considered diabetic.
Ultralente Iletin I U-100 insulin (Eli Lilly, Indianapolis, Indi-
ana, USA) was injected daily to all diabetic rats at a dose of 1.4
units subcutaneously (5 to 6 units per kg). Rats were allowed
free access to water and standard rat chow (Ralston Purina, St.
Louis, Missouri, USA). Total body weight and blood glucose,
measured between 9 and 10 a.m., were recorded every week.
Forty-eight-hour metabolic studies were performed at two and
four weeks to assess food intake and urinary protein, ketones,
sodium, and potassium excretion. At the end of the study (day
30) tail vein blood was obtained for measurements of serum
creatinine and plasma renin activity (PRA). The rats were then
sacrificed, kidneys were removed, snap-frozen in liquid nitro-
gen, and stored at —70°C for subsequent RNA extraction.
Experiment 2. This second experiment was performed to
determine PRA, tissue renin content (TRC), and intrarenal
distribution of renin and angiotensinogen mRNA in similarly
treated diabetic and control rats. Eleven male Sprague-Dawley
rats weighing 250 to 275 g were administered either STZ in
citrate buffer 65 mg/kg i.v. (Sigma) (diabetic group, N = 5) or
citrate buffer i.v. (control group, N = 6). Presence of diabetes
as well as weekly measurements of body weight and blood
glucose were performed as described in the previous experi-
ment. Insulin was also administered daily to the diabetic rats as
described. At the end of the study (day 30) tail vein blood was
obtained for PRA. The rats were then sacrificed, a portion of
the liver was removed, snap frozen in liquid nitrogen and stored
at —70°C for subsequent RNA extraction. The left kidney was
removed, weighed, snap-frozen in liquid nitrogen, and stored at
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—70°C for TRC determination. The right kidney was then
removed, the kidney tissue was minced into small (I jm3)
fragments in cold diethylpyrocarbonate-treated phosphate buff-
ered saline (PBS) and passed sequentially through 250 xm, 150
/zm, and then 75 jtm metal screens. The material was washed
through the screens with PBS. Those fragments trapped on the
75 im screen were employed for studies of glomeruli and those
fragments remaining on the 150 m screen were employed for
studies of tubules. Small elements of the vascular pole remain
attached to approximately 7% of glomeruli. Glomeruli and
tubules from rats of each group (diabetic group N = 5, control
group N = 6) were pooled to yield sufficient material for RNA
extraction (see below).
RNA extraction and Northern blot hybridization
Total RNA from the whole kidney or sieved glomeruli and
tubules was isolated using a modification of the guanidinium-
isothiocyanate/cesium chloride method 1261. The RNA was
dissolved in sterile water and RNA concentrations determined
by absorbance readings at 260 nm. Aliquots (20 gig) of total
RNA were electrophoresed in a 1% agarose gel containing 20
mM MOPS, 1 m'vi EDTA, 5 m'vi sodium acetate pH 7.0, and 2.2
M formaldehyde, and transferred to nylon membranes (Duralon
UVTM Stratagene, La Jolla, California, USA). In each gel,
equivalent loading of RNA, absence of degradation, and the
position of the 28 S and 18 S ribosomal RNA was determined by
ethidium bromide staining. RNA was fixed to the nylon mem-
brane by ultraviolet crosslinking (StratalinkerTM, Stratagene).
The membranes were prehybridized at 60°C for four hours in a
buffer containing 5x SSC, Sx Denhardt's reagent, 50 mM
Tris-hydrochioride, pH 7.5, 0.1% sodium pyrophospate, 0,2%
SDS, 200 tg/ml sonicated, denatured salmon testes DNA, and
100 ig/ml yeast tRNA. The membranes were then hybridized at
42°C with oligomer-primer labelled cDNA probes (see below)
for 16 to 18 hours in a buffer containing 50% deionized form-
amide, 5x SSC, lx Denhardt's reagent, 50mM Tris-hydrochlo-
ride, pH 7.5, 0.1% sodium pyrophosphate, 1% SDS, 100 Lg/ml
salmon testes DNA, and 100 ig/ml yeast tRNA. The mem-
branes were washed for 45 minutes in 2x SSC and 0.1% SDS
twice at room temperature and once at 60°C, and were then
washed in 0.2x SSC and 0.1% SDS at 60°C for 45 minutes.
Autoradiographs (Kodak XAR-5 film, Eastman Kodak Co.,
Rochester, New York, USA) were obtained and quantified by
computer assisted videodensitometry [271.
Solution hybridization
The presence of a single band for renin mRNA (1600 bp) on
hybridization of the nylon filters, permitted quantitation of
renin mRNA by solution hybridization based on a modification
of the technique of Durnam and Palmiter [281. This procedure
was performed to confirm results obtained by Northern analysis
and to more quantitatively assess total kidney renin mRNA in
diabetic and control rats. Total kidney RNA (25 to 60 g) was
hybridized for approximately 18 hours with 20,000 cpm of a
35S-labelled renin cRNA at 80°C in 20 d of 0.6 M NaCl, 10mM
Tris-HC1, pH 6.5, 5 mrvi EDTA, 2.5% ethanol, and 0.1% SDS.
The samples were digested with 1 ml RNase solution [RNase A
(25 tg/ml), RNase TI (250 U/mI), 0.3 M NaCI, 10mM Tris-HC1,
pH 7.5, 2 mrs'i EDTA, and 75 tg salmon testes DNAI to digest
unhybridized probe, precipitated with trichloroacetic-acid, and
quantified by liquid scintillation counting. A standard curve was
constructed and run with each assay using mRNA transcribed
by SP6 RNA polymerase after linearization of the renin plasmid
by Hind III, (2 to 10,000 pg).
cDNAs and preparation of the cDNA and cRNA probes
The following cDNA probes were used: rat renin (pRen
44.ceb) [291 rat angiotensinogen (pRANG 6) [301, (cDNAs were
a gift of K. R. Lynch), and mouse a-actin cDNA (pAM9l) [31].
For preparation of the cDNA probes, we utilized the method of
random oligomer-primer labelling (Promega, Madison, Wiscon-
sin, USA) with 32P-dCTP (6000 Ci/mmol; New England Nu-
clear, Dupont, Wilmington, Delaware, USA). Only gel isolated
insert eDNA was used in the labelling reactions. The specific
activity of the probes was 1 to 2 x io cpmIg DNA. For
preparation of the cRNA probe, the renin plasmid was first
linearized with the restriction enzyme BamilI. 250 Ci of 35S-
UTP (1320 Ci/mmol; New England Nuclear) was evaporated to
dryness in a microfuge tube and the following added: 1 tg of the
linearized cDNA, 2.5 d water, 2.0 .d 5x buffer (200 mM
Tris-HCI, pH 7.5, 30 mi'i MgCl2, 10mM spermadine), 1.0 d T7
RNA polymerase. The mixture was incubated for 60 minutes at
37°C. The reaction mixture was DNase-treated and unincorpo-
rated nucleotides removed by chromatography on a Sephadex
G50 column.
Biochemical methods
Serum creatinine was measured with a creatinine autoana-
lyzer (Beckman Instruments, Brea, California, USA). Urinary
protein was measured from aliquots of two consecutive 24-hour
urine collections using the Coomassie blue dye method (Bio-
Rad Laboratories, Richmond, Virginia, USA). Sodium and
potassium concentrations were measured also from aliquots of
two consecutive 24-hour urine collections, using a flame pho-
tometer.
PRA was determined at pH 6.0 by radioimmunoassay using a
commercially available kit (New England Nuclear). For deter-
mination of tissue renin content (TRC), the kidney aliquots
were kept at —70°C until their renin content was measured. The
kidney was homogenized in a buffer containing 2.6 mi EDTA,
1.6 miv dimercaprol, 3.4 mtvi 8-OH quinoline sulfate, 0.2 mM
PMSF, and 5 mM ammonium acetate, spun at 5000 rpm, and the
supernate was removed and frozen and thawed four times, a
procedure which does not activate prorenin [32]. TRC was
determined on an aliquot of supernatant after dilution to 1:1000
by the quantitation of generated angiotensin I (Rianen Assay
System, Du Pont Co., Billerica, Massachusetts, USA). Two
hundred d of the sample was incubated for one hour with 100
d of plasma obtained from nephrectomized male rats, 50 d 4%
EDTA, 10 d dimercaprol, 10 d 8-HO quinoline sulfate, and 630
d maleate buffer (pH 6.0). The protein concentration of the
supernatant was measured by the Coomassie blue dye method.
TRC per mg of protein was determined by dividing tissue renin
content by the protein concentration of the aliquot of kidney
assayed.
Statistical analysis
Statistical significance is defined as P < 0.05 and the results
are presented as mean standard error of the mean (±sEM).
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Fig. 1. A. Total body weight of diabetic (E) and control (•) rats at 0,
1, 2, 3, and 4 weeks after injection of STZ or citrate buffer. *p < 0.01.
B. Blood glucose of diabetic and control animals at 0, 1, 2, 3, and 4
weeks. P < 0.01.
The significance of the differences was analyzed by the Stu-
dent's t-test of unpaired data.
Results
Experiment I
General parameters and metabolic studies. As expected,
body weight in the diabetic rats decreased during the first two
weeks, then stabilized during the third week, and increased
thereafter. At all time points, control rats showed a significantly
higher body weight than diabetic rats. (Fig. 1A). Diabetic rats
were moderately hyperglycemic throughout the study (Fig. 1B).
Since blood glucose was only measured between 9 and 10 a.m.,
it is possible that higher glucose levels occurred at other times
of the day. No urinary ketones were present in the 24-hour
urine samples obtained at week 2 and week 4. Table I shows the
results of the 48-hour metabolic studies performed at two and
four weeks of the study. Food intake, urinary volume, urinary
Na and K excretion and urinary protein excretion were all
significantly increased in the diabetic rats as compared to
control animals, at both time points (Table 1). The left kidney
weight was also significantly increased in the diabetic compared
to the control group when expressed as both absolute weight
(diabetic: 1.35 0.03 vs. control: 1.17 0.01 g; P <0.001) and
as kidney weight/body weight ratio (diabetic: 5.06 0.08 vs.
control: 3.51 0.07 x i03; P < 0.001). Serum creatinine was
Table 1. Metabolic studies
Diabetes Control
(N=8) (N=5)
Food intake g 2 weeks
4 weeks
36.5 l.6a
39.8 1.9'
20.5 0.8
18.4 1.1
Urinary protein 2 weeks 44.6 2.7a 18.3 1.8
mg124 hr 4 weeks 41.8 46' 20.0 2.4
Urinary Na 2 weeks 3.1 0.3' 1.5 0.1
mEq/24 hr 4 weeks 2.5 0.2' 1.6 0.1
Urinary K 2 weeks 5.7 0.3' 2.9 0.3
,nEq/24 hr 4 weeks 5.7 0.4' 3.5 0.2
Values are mean SEM. Results of 48-hour metabolic studies
performed at 2 and 4 weeks. Food intake, urinary protein, Na and K
excretion were all significantly increased in the diabetic rats at both
time points.
'P < 0.001
not different at the end of the study between the two groups
(diabetic: 0.5 0.01 vs. control: 0.5 0.04 mg/dl; P NS).
Northern hybridization. Analysis of Northern blots con-
firmed a single band for renal renin mRNA (1600 bp), and renal
and liver angiotensinogen mRNA (1800 bp), and a predominant
band for ct-actin mRNA (2200 bp). Figure 2 shows an autorad-
iograph of a northern blot of total kidney RNA extracted from
diabetic and control rats, which has been hybridized with a
renin eDNA probe. Each lane corresponds to one rat. Quanti-
tation by computer assisted videodensitometry demonstrated
that renin mRNA was not different between the diabetic and the
control group (diabetes: 435 45 vs. control: 432 36 O.D.
units; P = NS; Fig. 2). The same Northern blot was hybridized
with an angiotensinogen eDNA probe, after allowing sufficient
time for the initial radioactivity to decay. Angiotensinogen
mRNA was significantly lower in the diabetic group (diabetes:
294 22 vs. control: 508 53 O.D. units; P < 0.01; Fig. 3). An
identical Northern blot was hybridized with an cs-actin eDNA
probe to serve as a control for the integrity of the RNA. a-Actin
mRNA was not different between the two groups (diabetes:
1286 96 vs. control: 1250 135 O.D. units; P = NS).
Figure 4 shows an autoradiograph of a Northern blot of total
liver RNA extracted from diabetic (N = 6) and control (N = 5)
rats, hybridized with an angiotensinogen eDNA probe. Quan-
titation by computer assisted videodensitometry demonstrated
that angiotensinogen mRNA was lower in the diabetic group
(diabetes: 1199 60 vs. control: 2462 119 O.D. units; P <
0.01). No difference in liver a-actin was detected between the
diabetic and control group (57.9 7 vs. 54.9 6.4 O.D. units;
P = NS).
Solution hybridization. Renin mRNA was quantitated by
solution hybridization in the diabetic and control rats. Renin
mRNA was not different between the two groups (diabetes: 2.32
0.16 vs. control: 1,89 0.12 pg/pg RNA; P NS),
confirming the results of northern analysis.
PRA measurement. PRA was significantly lower in the dia-
betic rats (diabetes: 4.29 0.63 vs. control: 7.00 0.76 ng
Al/ml/hr; P < 0.02).
Experiment 2
Northern hybridization of glomeru/ar and tubular RNA.
Renin mRNA was detected in glomerular and tubular fractions
of both diabetic and control animals. Although renin-like activ-
ity has been detected in proximal tubular cells [331, the renin
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Fig. 2. Autoradiograph of Northern blot of
total kidney RNA (20 p.g) extracted from eight
diabetic and five control rats. A 32P random
oligomer-primer labelled renin cDNA probe
was used for hybridization. Quantitation by
videodensitometry showed that the relative
renin mRNA level was not different between
the two groups (P = NS).
Fig. 3. Autoradiograph of Northern blot of
total kidney RNA (20 pg) extracted from eight
diabetic and five control rats and hybridized
with an angiotensinogen cDNA probe.
Angiotensinogen mRNA level was
significantly lower in the diabetic rats (P <
0.01).
mRNA present in the tubular fraction may represent arteriolar
contamination. Since the samples were pooled, no statistical
analysis was possible but the respective values as determined
by videodensitometry were similar between the diabetic and the
control group (diabetic glomerular renin mRNA, 1042 vs.
control glomerular renin mRNA, 974; diabetic tubular renin
mRNA, 607 vs. control tubular renin mRNA, 904 O.D. units;
Fig. 5A). Angiotensinogen mRNA was detected in tubular RNA
of both diabetic and control animals and was higher in the
control group (diabetic tubular angiotensinogen mRNA, 71 vs.
control tubular angiotensinogen mRNA, 182 O.D. units; (Fig.
5B). a-Actin mRNA was higher in glomerular than in the
tubular samples in both diabetic and control rats. The levels of
cs-actin were similar for both glomerular and tubular fractions
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Fig. 4. Autoradiograph of Northern blot of
total liver RNA (20 aug) extracted from eight
diabetic and five control rats and hybridized
with an angiotensinogen cDNA probe.
Angiotensinogen mRNA level was
significantly lower in the diabetic rats (P <
0.01).
between the diabetic and the control group (diabetic glomerular
a-actin mRNA, 1898 vs. control glomerular a-actin mRNA,
1996; diabetic tubular a-actin mRNA, 737 vs. control tubular
a-actin mRNA 926, O.D. units; Fig. 5C). Equivalent loading
and integrity of the RNA was determined by ethidium bromide
staining (Fig. 5D).
PRA and TRC measurement. Figure 6 shows the results of
PRA and TRC obtained in this experiment. PRA, as seen in the
previous experiment, was significantly lower in the diabetic rats
(diabetes: 2.30 0.30 vs. control: 6.93 1.36 ng Al/ml/hr; P <
0.01; Fig. 6A). In contrast, TRC was not different between the
two groups (diabetes, 1.81 0.46 vs. control, 2.05 0.27 g
Al/mg protein/hr; P < 0.05; Fig. 6B).
Discussion
The present study examined components of the systemic and
local renin-angiotensin system four weeks after induction of
diabetes by STZ in rats maintained moderately hyperglycemic
with exogenous insulin. In comparison to a non-diabetic control
group, PRA was significantly lower in the diabetic animals. In
the kidney, TRC and renin mRNA (a marker of local renin
synthesis) were not different in the diabetic compared to the
non-diabetic animals. No increase in glomerular renin mRNA
was observed between the diabetic and control rats. Angioten-
sinogen mRNA was lower in whole kidney, the renal tubular
RNA fraction, and livers of the diabetic rats. Thus, no evidence
was found for activation of the local renal renin-angiotensin
system in diabetes, although some discrepancy between the
systemic and intrarenal systems was observed for renin, with
decreased PRA yet no fall in TRC or renal renin mRNA in the
diabetic compared to the non-diabetic controls.
The renin-angiotensin system has an important role in the
regulation of the renal microcirculation. Angiotensin II (Ang
II), a potent renal vasoconstrictor, has preferential effects on
the efferent arteriole [13, 14]. Therefore, increased action of
Ang II would be manifested by increased efferent arteriolar
constriction with consequent elevation in glomerular capillary
pressure. Glomerular hypertension has been implicated in the
progression of several glomerular diseases including diabetic
nephropathy [4, 9—121. Marked renal hemodynamic changes
accompany experimental diabetic renal disease. In the moder-
ately hyperglycemic rat, elevations in single nephron plasma
flow and glomerular pressure lead to elevations in glomerular
filtration rate [9]. These hemodynamic changes are secondary
to the imbalance of resistances at the pre- and postglomerular
levels with a greater dilatation occurring in the afferent com-
pared to the efferent arteriole. Treatment of diabetic rats with
angiotensin converting enzyme inhibitors (CEI) or Ang II
blockers, but not other antihypertensives, decreases glomerular
pressure and is associated with amelioration of renal injury
[10—12, 15]. The greater decrease in afferent compared to
efferent resistance and the beneficial response to maneuvers
which decrease Ang II, suggest a role for the renin-angiotensin
A Renin mRNA B Angiotensinogen mRNA
Sham Diabetes Sham Diabetes
C a-Actin mRNA
Sham Diabetes
g t g
t g t
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t g t g
t
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Fig. 5. A. Autoradiograph of Northern blot of
pooled samples of glomerular and tubular
RNA (20 sag) extracted from diabetic (N = 5)
and control rats (N = 6) and hybridized with
a renin cDNA probe. B. Autoradiograph of
same Northern blot, hybridized with an
angiotensinogen cDNA probe. C.
Autoradiograph of same Northern blot,
hybridized with an s-actin cDNA probe. D.
Photograph of ethidium bromide stained
Northern gel of glomerular and tubular RNA.
system in the development and progression of diabetic renal
disease.
The local intrarenal renin-angiotensin system may participate
in the regulation of renal function independent of its systemic
counterpart [25]. Preliminary studies examining the renin-angi-
otensin system in the diabetic kidney have yielded conflicting
results. Anderson and coworkers reported increased renal renin
content and angiotensinogen mRNA in insulin-treated diabetic
rats six to eight weeks following STZ-induced diabetes. In that
study, chronic Ang II blockade decreased glomerular pressure
independent of changes in systemic pressure [15]. Sajid and
collaborators examined the time course of renin and angioten-
sinogen expression following induction of diabetes by STZ.
Renin mRNA and renal and liver angiotensinogen mRNA were
suppressed from days 1 to 42 and then normalized [16]. Sechi
and coworkers reported no change in angiotensinogen and renin
mRNA in untreated diabetic rats compared to insulin-treated
diabetic or control rats 12 days after STZ. The untreated
diabetic group did have a decrease in All receptors and an
increase in prorenin compared to the other two groups [17]. In
spontaneously diabetic BB rats, Everett and coworkers dem-
onstrated an initial increase in renal renin and angiotensinogen
mRNA, and renin stained cells per juxtaglomerular apparatus,
which later decreased during the more chronic phase of diabe-
tes [181. Finally, Jaffa and coworkers demonstrated that three
weeks after the induction of diabetes with STZ, severely
hyperglycemic rats had low renin mRNA while moderately
hyperglycemic (insulin treated) rats had a renin mRNA level not
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Diabetes Control
N=5 N=6
Fig. 6. A. PRA in diabetic and control rats. PRA was significantly
lower in rats with diabetes as compared to control rats (P < 0.02). B.
TRC in diabetic and control rats. TRC was not different between the
two groups (P = NS).
different from control. This same group reported that the
insulin-treated diabetic rats had a plasma renin content not
different from that of the control group, however, renal renin
content was significantly increased [191. All of these discrepan-
cies are not readily explained given the preliminary nature of all
of these reports. However, differences may be related to the
varying time periods at which the rats were studied, the degree
of glycemic control, dietary intake, and the diabetic model
studied.
Based on measurements of components of the systemic and
intrarenal renin-angiotensin system, we could find no evidence
for activation of this system in our insulin-treated diabetic rats
compared to control rats. However, the dissociation between
the fall in plasma renin activity with no decrease in renal renin
content or renin mRNA suggests a lack of suppression of the
intrarenal system compared to its systemic counterpart. Renal
renin mRNA was expressed in the conventional fashion as a
proportion of total RNA. Since hypertrophy occurs in the
diabetic kidney, the total amount of renal RNA, and therefore
renin mRNA, would be greater in the diabetic compared to the
control rat, further emphasizing the discrepancy between sys-
temic and renal renin. These findings are compatible with a
decrease in prorenin conversion to active renin that could
contribute to the increased plasma levels of prorenin demon-
strated in diabetic rats and patients [17, 34—37]. A prorenin to
renin conversion defect could explain the lower active renin
level in the face of normal to elevated levels of renal renin
mRNA. An abnormal prorenin response to diuretics has been
demonstrated in some diabetic patients, and this phenomenon,
as well as hyporeninemic hypoaldosteronism often found in
diabetic patients, may both derive from some defect in activa-
tion of renin [361. An alternative explanation for this dissocia-
tion between a low PRA and no change in TRC or renin mRNA
could be a reduced amount of substrate (angiotensinogen)
available for renin action in the assay. Although renin substrate
availability is not thought to be rate limiting in the generation of
angiotensin I, the lower liver angiotensinogen mRNA present in
the diabetic rats raises this possibility. Finally, a more distal
defect in renin secretion and/or increased peripheral renin
clearance might also account for the lower plasma compared to
renal renin, however, there is no clear reason to suspect the
latter possibility [381. The examination of glomerular versus
tubular expression of renin mRNA was performed in the
present study to determine if renin synthesis shifted into
diabetic glomeruli. We felt it was important to test for this
possibility as we have previously documented a shift of renin
synthesis into the glomeruli of rats following subtotal nephrec-
tomy [39], another model characterized by low plasma renin
activity yet exhibiting a beneficial renal response to angiotensin
converting enzyme inhibition. No difference in glomerular renin
mRNA was found in the diabetic compared to the non-diabetic
rats speaking against any diabetes-related intraglomerular shift
of renin synthesis.
As expected, the diabetic rats had higher food intakes than
the non-diabetic controls. Since both dietary sodium and pro-
tein modulate renin synthesis, the changes in renin may be
influenced by these dietary components [40, 41]. For example,
isolated increases in sodium intake would be expected to
decrease renal renin and angiotensinogen, while a higher pro-
tein intake is associated with increased renal renin mRNA but
no change in angiotensinogen mRNA [40, 41]. The interactions
between these dietary components and the diabetic state were
not specifically dissected in this current study, but the pattern
of results does not suggest that either increased protein intake
or salt imbalance are solely responsible for the changes in the
components of the renin-angiotensin system measured.
Although quantitation of renin protein or mRNA does not
provide definitive evidence for increased Ang II production,
renin is the rate-limiting enzyme in the formation of Ang II.
Furthermore, measurement of renal renin provides information
about local renin synthesis in the kidney [25]. Definitive evi-
dence for a pathogenetic role of the renin-angiotensin system
rests on the results of studies examining specific blockade of
this system. Studies of this nature suggest that the renin-
angiotensin system is activated in diabetes [11, 12, 15]. How-
ever, most of the components of this system including systemic
and renal renin and renin mRNA, renal angiotensinogen
mRNA, liver angiotensinogen mRNA, and Ang II receptor
number and affinity are either unchanged or decreased in
diabetic compared to non-diabetic animals [16—22, 42]. This
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apparent discrepancy may be explained by post-receptor
events. Alternatively, a number of other diverse vasoactive
systems may be playing a role in the modulation of intrarenal
hemodynamics in diabetes including increased glomerular pros-
taglandin production [5, 6], activation of the kallikrein system
[8], increased atrial natriuretic peptide [7], and decreased
sensitivity of tubuloglomerular feedback conditioned by glu-
cose delivery to the macula densa [43]. Therefore, even without
marked elevations in the components of the renin-angiotensin
system, removing the effects of this system may alter the
critical balance between vasoconstrictor and vasodilator sys-
tems.
Evidence implicating the renin-angiotensin system in the
pathogenesis and progression of diabetic nephropathy in hu-
mans derives primarily from studies of CEI therapy and from
measurements of renin and prorenin. Treatment with CEI
reduces proteinuria in both normotensive and hypertensive
diabetics and is associated with a decrease in the rate of decline
in renal function [43—48]. In diabetic patients, PRA has been
reported as being low, normal and high [21—24]. The higher
values have been noted in diabetics with glomerular hyperfil-
tration [231. Since early increases in GFR are associated with
later development of nephropathy [49], the increase in PRA
may be playing a pathogenetic role in the development of
diabetic nephropathy. Elevations in circulating prorenin have
been demonstrated in diabetics [34—37]. These increased prore-
nm values, independent of changes in active renin, have been
regularly associated with the presence and development of
diabetic microvascular complications [34, 35, 37]. As noted, the
high prorenin and normal to low active renin found in some
human diabetics, taken together with our findings of a decrease
in PRA but no difference in renal renin content or renin mRNA,
raises the possibility of a defect in conversion of prorenin into
active renin. Furthermore, one might speculate that such a
defect could contribute to the heightened prorenin levels noted
in complicated human diabetes.
In conclusion, insulin-treated diabetic rats had lower PRA
but no change in TRC or renal renin mRNA compared to
non-diabetic controls. Both renal and liver angiotensinogen
mRNA were lower in the diabetic group. The dissociation
between a decrease in systemic but no change in renal renin in
the diabetic rats is consistent with alterations in intrarenal renin
processing and/or secretion by the diabetic kidney.
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